Navigation Links
Cystic Fibrosis Foundation Launches National Cycling Series to Benefit Critical Research and Care
Date:5/3/2010

Eurand Donates $300,000 as Title Sponsor of ZENPEP(R) CF Cycle for Life

BETHESDA, Md., May 3 /PRNewswire-USNewswire/ -- Thousands of cyclists will take to the streets this summer and fall as the Cystic Fibrosis Foundation launches a new cycling tour in 18 cities across the country to support research to find new therapies and a cure for cystic fibrosis. The tour series, known as ZENPEP® CF Cycle for Life, begins in San Francisco on June 26.

The event's title sponsor is Eurand N.V., a global specialty pharmaceutical company, which makes ZENPEP® (pancrelipase) Delayed-Release capsules, a pancreatic enzyme replacement therapy.

"Eurand is proud to serve as national sponsor of the inaugural ZENPEP CF Cycle for Life series," said Ruth Thieroff-Ekerdt, M.D., Eurand's Chief Medical Officer. "We're pleased to support the Cystic Fibrosis Foundation in its efforts to advance life-saving medical research for CF and develop therapies that have the potential to add decades of life for those with this devastating disease."

The touring series offers cyclists several mileage options – 30 or 65 miles, as well as scenic routes, training rides, cycling "how-to" clinics, safety inspections and lots of day-of support and activities.

"We are grateful to Eurand for joining our team and supporting our effort to bring cycling enthusiasts to the fight against cystic fibrosis," said C. Richard Mattingly, executive vice president and chief operating officer of the Cystic Fibrosis Foundation. "The company's generous support means we can expand our already robust drug development effort as we aggressively invest in new ways to fight and eradicate this horrific disease."

Cycling tours will take place this year in: Atlanta, Ga., Baton Rouge, La., Boston, Mass., Charleston, S.C., Denver, Colo., Dayton, Ohio, Grand Rapids, Mich., Hartford, Conn., Jacksonville, Fla., Portland, Ore., Malvern, Pa., Peoria, Ill., Phoenix, Ariz., San Diego, Calif., San Francisco, Calif., Seattle, Wash., Tampa, Fla., and Tyler, Texas.

ZENPEP is an FDA-approved pancreatic enzyme therapy used for treatment of exocrine pancreatic insufficiency from CF or other conditions. More than 90 percent of people with cystic fibrosis take enzyme supplements to help absorb vitamins and nutrients, and could not survive without them.

For more information about ZENPEP CF Cycle for Life, visit

http://www.cff.org/aboutCFFoundation/PressRoom/2010PressReleases/05-03-CF-Foundation-Launches-Cycling-Series.cfm

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. For more information, visit www.cff.org.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit Eurand's website at www.eurand.com.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
2. PARI Pharmas Altera Delivers Gileads Cayston, Approved by the U.S. FDA for the Improvement of Respiratory Symptoms in Cystic Fibrosis Patients With Pseudomonas aeruginosa
3. CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis
4. Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis
5. Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks
6. Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
7. Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial
8. Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Nanoemulsion Kills Highly Resistant Bacteria Found in Patients With Cystic Fibrosis
11. PTC Announces Data Showing That PTC124 Causes Statistically Significant Improvements in Chloride Channel Function in Cystic Fibrosis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... , Kalifornien, 12. Februar 2016  Sequent ... der Aufnahme von Patienten für eine Studie zur ... Aneurysmen („WEB") speziell für die Behandlung von rupturierten ... , MD, Leiter der Neuroradiologie an der Universitätsklinik ... und Hauptprüfarzt der CLARYS-Studie hat den ersten Patienten ...
(Date:2/12/2016)... , Feb. 12, 2016  Eli Lilly and Company ... Court decided the Alimta® (pemetrexed disodium) vitamin regimen patent would ... the UK, France , Italy ... to dilute the product only with dextrose solution.  ... 2015, the UK Court of Appeal held that Lilly,s patent ...
(Date:2/12/2016)... BUDAPEST , Ungarn, February 12, 2016 ... ein Medizintechnikunternehmen, das sich auf den ungedeckten ... gab heute positive Ergebnisse seines klinischen Forschungsprogramms ... und Asthma-Patienten beschäftigt, ergab Verbesserungen ihrer respiratorischen ... Indiso ltd , ein Medizintechnikunternehmen, das ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... ... DDi , a Makro company, makes it to ... in eClinical Solutions. DDi has built its solution competency with a unique blend ... DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by providing ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... devoted exclusively to funding innovative lymphoma research and serving the lymphoma community through ... over 250 members of South Florida’s philanthropic community at its 10th anniversary Fashion ...
(Date:2/12/2016)... ... 2016 , ... Coco Libre, the maker of coconut water beverages with a ... Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut ... invitation-only gifting suite, held this year at the W Hollywood Hotel, has become a ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman ... John J. Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, ... VA Southern Nevada Healthcare System. This will be the first Fisher House in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
Breaking Medicine News(10 mins):